Introduction
============

Colorectal cancer (CRC) is the third most common malignant disease, estimated to affect approximately 135,430 people and causes more than 50,260 deaths in the United States in 2017 [@B1]. The majority of deaths from colorectal cancer are associated with tumor cell metastasis and resistance to chemotherapy [@B2], [@B3]. Numerous studies have suggested that cancer stem-like cells (CSCs) mediate resistance to conventional therapies, drive tumor cell metastasis, and promote tumor recurrence in CRC [@B4]-[@B6]. Therefore, CSCs represent promising targets for effective prevention and treatment against colorectal cancer [@B7]. However, efficient and specific drugs for use in the clinic are still lacking.

Aspirin is a non-steroid anti-inflammatory drug (NSAID) with a number of indications including analgesia and cardiovascular prophylaxis. Epidemiological studies have suggested that the daily use of aspirin reduces the risk and overall mortality of CRC [@B8]-[@B10]. This favorable outcome has been reported to be related to aspirin therapy after diagnosis of colorectal cancer [@B11]-[@B13]. In addition, the daily use of aspirin (≥75 mg) was also observed to reduce the risk of distant metastasis in subsequent follow-ups of CRC patients without initial metastasis [@B14]. Thus, these studies indicate that aspirin can serve as a promising adjuvant therapy in CRC. Considering the major roles of CSCs in driving the incidence, mortality, and metastasis of CRC, it prompts us to know whether aspirin exerts an anti-cancer effect by targeting CSCs. It had been reported that aspirin inhibited colosphere formation in SW620 in CRC [@B15]. However, the evidence from patients with aspirin therapy is still lacking and the mechanism by which aspirin inhibits CSCs remains obscure.

Multiple models of action have been proposed to explain the anti-carcinogenic effects of aspirin in normal tumor cells [@B16]. The prostaglandin system and the cyclooxygenase enzyme COX-2 that oxidize arachidonic acid to prostaglandin, which are the central mechanisms of aspirin, are believed to be involved [@B17]-[@B20]. Other COX-2-independent mechanisms of the anti-neoplastic effects of aspirin have also been reported, such as inhibition of Wnt/β-catenin, and mTOR pathways [@B21]-[@B25] and activation of the AMPK pathway [@B25]. Finally, aspirin differs from other NSAIDs and can acetylate multiple cellular molecules including p53, histones, and immunoglobulins [@B26]-[@B30], which could also contribute to its anti-cancer mechanisms. Among these aforementioned mechanisms of action, how aspirin-induced anti-neoplastic effects are mediated in CSCs and its target still needs to be investigated.

In this study, we aimed to test the effect of aspirin on CSCs, decipher the mechanism behind these effects and demonstrate its potential to serve as an adjuvant therapy in CRC.

Methods
=======

Reagents
--------

Aspirin (Sigma) was dissolved in water using 10 N NaOH, and the pH was adjusted to 7.0. Secondary antibodies containing anti-rabbit IgG or anti-mouse conjugated to horseradish peroxidase, mammalian protein extraction reagent (MPER) lysis buffer, Halt protease inhibitor cocktail, and stripping buffer were obtained from Pierce (Rockford, IL, USA).

Primary colon cancer cell preparation and cell lines
----------------------------------------------------

The P1and P2 cells were primary cancer cells isolated from human colon adenocarcinoma specimens obtained during surgical procedures, which was approved by the Research Ethics Board at Second Affiliated Hospital of Zhejiang University School of Medicine. The preparation of primary tumor cells was performed as described previously [@B4], [@B31]. P1 cancer cells were cultured in RPMI-1640 (Invitrogen, Grand Island, NY) medium containing 10% FBS. P2 cancer cells were maintained in Dulbecco\'s modified Eagle\'s medium (Invitrogen, Grand Island, NY) with 10% FBS. Colon cancer cell line HT29 was purchased from the American Type Culture Collection and maintained in McCoy\'s 5A (Invitrogen, GrandIsland, NY) medium containing 10% FBS at 37 °C and 5% CO~2~.

Tumorsphere-forming assay
-------------------------

The tumorsphere-forming assay was performed as follows: cells were collected and washed to remove serum and then suspended in ultralow-attachment flasks in serum-free medium (SFM) (DMEM/F12 containing nonessential amino acids, antibiotic-antimycotic, N2 supplement (Invitrogen), B27 supplement (Invitrogen), heparin (4 μg/mL; Sigma), epidermal growth factor (20 ng/mL; Invitrogen), and basic fibroblast growth factor (10 ng/mL; Invitrogen)) at 37 ° C and 5% CO~2~.

Xenograft mouse model
---------------------

Six-week-old female Balb/c athymic nude mice were purchased from and bred in defined conditions at the Laboratory Animal Research Center of Zhejiang Chinese Medicine University with the permission from the local animal care and ethical committee. Equal numbers (1×10^5^) of CSCs were suspended in 100 μL Matrigel diluted to 1:1 in serum-free DMEM/F-12 and subcutaneously injected into the left rear flank of each mouse. 10 days after cell injection, the tumors reached a palpable size. A total of 16 mice were randomly assigned to receive either (1) control treatment or (2) aspirin treatment. Aspirin was injected once a day by intraperitoneal injection at a dosage of 20 mg/kg/body weight, which is equivalent to a daily human dosage of 80-110 mg. (3) Oxaliplatin treatment (once a week, 2 mg/kg/body weight) or (4) oxaliplatin combined aspirin treatment. Oxaliplatin was injected once a week by intraperitoneal injection at a dosage of 2 mg/kg/body weight. Aspirin was injected once a day by intraperitoneal injection at a dosage of 20 mg/kg/body weight. All groups received treatments for 4 weeks, tumors were measured by a slide gauge every 3 days and their volume was calculated as length×width×width/2. All mice were then euthanized by cervical dislocation.

Design and construction of plasmids in locus-specific histone acetylation
-------------------------------------------------------------------------

The SID4X-dCas9 and CIB1-dCas9 were constructed by replacing FokI in the FokI-dCas9 plasmid (Addgene52970) [@B32] with SID4X and CIB1 cDNA fragments amplified by PCR from LITE1.0_pAAV_hSyn_CRY2PHR-NLS-SID4X_2A_phiLOV2.1_WPRE_bGHpA plasmids (Addgene47454) and LITE2.0_pAAV_hSyn_TALE(Grm2)-GS-CIB1(NLS\*,∆318-334)\_WPRE_bGHpA plasmids (Addgene47456) [@B33]. The primers used for the above PCR amplifications were as follows: SID4X-forward: 5\'-GACGATGACAAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTGGAGGTTCTGGATCCATGAACATCCAGATGCTGCTG; SID4X-reverse: 5\'-AGCTAAACCAATAGAATACTTTTTATCACTTTCGGGTGTGGCGGACTCTGAGGTCCCGGGAGTCTCGCTGCCGCTGGGCAGCATAGAGGCATAGCC; CIB1-forward: 5\'-GACGATGACAAGATGGCCCCCAAGAAGAAGAGGAAGGTGGGCATTCACCGCGGGGTACCTGGAGGTTCTGGATCCAACGGCGCGATTGGTGGGGATTTG; CIB- reverse: 5\'-AGCTAAACCAATAGAATACTTTTTATCACTTTCGGGTGTGGCGGACTCTGAGGTCCCGGGAGTCTCGCTGCCGCTACTGGAAGTATTCACCTGCTG.

gRNA-SID4X-dCas9 and gRNA-CIB1-dCas9 were then generated by introducing a chimeric gRNA cassette into the SID4X-dCas9 or CIB-dCas9 plasmids following PCR amplification of the px330 plasmid (Addgene42230). The gRNAs vectors were designed and further constructed according to a published protocol [@B34]. Briefly, a pair of oligos targeting the *FasL* promoter sequence were annealed and phosphorylated and then further cloned into the BbsI sites of px330. The primer sequences for gRNA cloning were as follows:

gRNA1 forward: CACCGCATAGCCTACTAACCTGTT, gRNA1 reverse: AAACAACAGGTTAGTAGGCTATGC; gRNA2 forward: CACCGTAGGCTATGCTCACCTTCC, gRNA2 reverse: AAACGGAAGGTGAGCATAGCCTAC; gRNA3 forward: CACCGACAGCAACTGAGGCCTTGA, gRNA 3 reverse: AAACTCAAGGCCTCAGTTGCTGTC; gRNA4 forward: CACCGGCTGTTATCAGAAAATTGT, gRNA4 reverse: AAACACAATTTTCTGATAACAGCC.

Light-inducible, locus-specific histone modification
----------------------------------------------------

Light-induced histone modification was performed similarly to a previous report [@B33], [@B35]. Briefly, cells were illuminated using a custom-built LED array aligned to a 6-well cell culture plate. LEDs were driven by a waveform generator (Rigol DG1022U) and powered by a DC power supply (Arksen 305D). Illumination was measured using a Thorlabs PM200 Power Meter and a S120C Power Sensor. The temperature inside the wells was measured using BMDS wireless temperature probes. Plates containing cells incubated in the dark were wrapped in aluminum foil. The following stimulation parameters were used for experiments: 466 nm, 5 mW/cm^2^ for 24 h. Pulses were delivered at 0.067 Hz with a duration of 7% corresponding to 1 s pulses.

Immunostaining
--------------

Tissue sections (5 μm) were deparaffinized, rehydrated, and treated with 3% hydrogen peroxide, followed by antigen retrieval in boiling 0.1 M citrate (pH 6.0) buffer for 10 min twice. The sections were then blocked with 20% goat/rabbit serum for 30 min. Immunostaining was performed as previously described [@B36]; antibodies against ALDH1 (1:100; Abcam,ab195255) or DLCK1(1:100; Abcam,ab31704 ) were used. The ratio of positively stained cells to tumor cells was scored and reported as the mean ± SEM.

Clinical samples
----------------

Paraffin specimens of CRCs from 18 patients who were taking aspirin (100 mg/day) and 20 patients who were not taking aspirin were obtained from the Pathology Department of the Second Affiliated Hospital, Zhejiang University School of Medicine. The pathologic type was adenoma and verified by the pathologist. All tissue samples and the experimental protocol were approved by the Review Board of the Second Affiliated Hospital of Zhejiang University, and written informed consent was obtained for each patient.

Statistics
----------

Statistical analysis was performed using GraphPad Prism software.

Results
=======

Aspirin eliminates colorectal cancer stem-like cells
----------------------------------------------------

To test the effects of aspirin treatment on colorectal CSCs in human patients, we recruited 18 patients with CRC who were taking 75-100 mg aspirin daily and 20 patients with CRC who were not taking aspirin. The clinical characteristics of the patients are shown in **Table [S1](#SM0){ref-type="supplementary-material"}**. We found that the percentage of stem cell marker-positive cells (ALDH1+, DLCK1+) in the patients taking aspirin decreased by almost 18-fold (from 18% to 1%) (**Figure [1](#F1){ref-type="fig"}A**) and 10-fold (from 10.6% to 1.3%) (**Figure [1](#F1){ref-type="fig"}B**). In addition, the ratios of lymph node metastasis (N1/N2) and advanced CRC (III/IV) were significantly decreased in the patients taking aspirin (p=0.041 and p=0.007, respectively) (**Figure [S1](#SM0){ref-type="supplementary-material"}C-D**). These results indicate that the CRC patients taking aspirin had a lower percentage of CSCs and a better prognosis.

To determine the effects of aspirin treatment on colorectal CSCs, 3 different adherent cells (ACs) were incubated in serum-free medium. A small percentage of cells are able to form tumor spheres, and thus, are termed tumorsphere cells (TCs) (**Figure [1](#F1){ref-type="fig"}C** and **Table [S1](#SM0){ref-type="supplementary-material"}**). In accordance with our prior characterization [@B31], TCs exhibited enhanced tumor sphere formation ability (**Figure [1](#F1){ref-type="fig"}D**), highly expressed the major stem cell markers (**Figure [1](#F1){ref-type="fig"}E** and **Figure [S1](#SM0){ref-type="supplementary-material"}A**) and showed higher tumorigenicity *in vivo* compared with their respective ACs (**Figure [S1](#SM0){ref-type="supplementary-material"}B**). These results suggest that TCs fulfill the characteristics of CSCs. Then, we treated TCs with different concentrations of aspirin, and found that aspirin markedly reduced both the number and the diameter of the tumor spheres in a dose-dependent manner (**Figure [1](#F1){ref-type="fig"}D**). Secondly, aspirin decreased the expression of stem genes (*Sox2*,*Oct4*,*Nanog*,*Notch1*, *Bmi-1,* and*ALDH1*) (**Figure [1](#F1){ref-type="fig"}F**). Thirdly, we used the ALDEFLUOR assay to detect cells with ALDH activity in each group (**Figure [1](#F1){ref-type="fig"}E**) and found that aspirin significantly decreased the ratio of ALDH1 high activity CSCs from HT29 or P1 cell lines. In addition, the Lgr5+ and CD166+ expressing cell population was significantly enriched in TCs and greatly reduced following 14 days of incubation with 5 mM aspirin (**Figure [S1](#SM0){ref-type="supplementary-material"}A**). Limiting dilution assay also showed that aspirin treatment notably decreased the population of CSCs (**Table [S2](#SM0){ref-type="supplementary-material"}**). Lastly, we found that the tumor volumes significantly decreased in the groups administered aspirin (20 mg/kg/body weight, which is equivalent to a daily human dosage of 80-110 mg) (**Figure [1](#F1){ref-type="fig"}G**). Taken together, these results demonstrate that aspirin exerts inhibitory effects on colorectal CSCs.

Aspirin induces apoptosis in CSCs
---------------------------------

We next compared the inhibitory effects of aspirin in ACs and TCs and found that aspirin treatment decreased cell viability of both ACs and TCs in time- and dose-dependent manners (**Figure [2](#F2){ref-type="fig"}A**). Following incubation with aspirin, there were significantly fewer viable TCs than ACs at the tested time points. In addition, high ALDH1 activity positive cells were markedly decreased following 5 mM aspirin treatment and were nearly completely depleted at 10 mM aspirin (**Figure [2](#F2){ref-type="fig"}B**). These results demonstrate that aspirin could inhibit both colorectal CSCs and non-CSCs, but colorectal CSCs are more vulnerable to aspirin.

To better elucidate the inhibition of aspirin on CSCs, we performed TUNEL assays to investigate whether aspirin inhibits TCs by inducing apoptosis, which has been suggested to be responsible for aspirin-induced cell death [@B37]. TUNEL-positive cells were markedly increased in TCs following incubation with aspirin (**Figure [2](#F2){ref-type="fig"}C-D**). We next compared aspirin-induced apoptosis of TCs with that of ACs. Following 5 mM aspirin treatment, more apoptotic TCs (54.5%) were readily detected than ACs (8.4%) following 96 h treatment (**Figure [2](#F2){ref-type="fig"}E**). The results in **Figure [S2](#SM0){ref-type="supplementary-material"}A-B** also showed that less apoptosis was observed in ACs than TCs (**Figure [2](#F2){ref-type="fig"}C-D**) after 5 mM aspirin treatment for 48 h. These data demonstrate that aspirin inhibits TCs by inducing apoptosis, and TCs are more vulnerable to aspirin-induced apoptosis than regular ACs.

Aspirin-induced apoptosis in CSCs is mediated by FasL
-----------------------------------------------------

To determine the apoptotic mechanisms, we screened a series of genes that have been reported to mediate aspirin-induced apoptosis, including *Bcl-2*,*Bax*, *Fas*,*FasL*, *caspase-3*,*caspase-8* and*caspase-9* [@B37]-[@B39]. Among these genes, *FasL*,*Fas*,*caspase-3* and *caspase-8* were significantly increased in TCs (**Figure [3](#F3){ref-type="fig"}A**). Interestingly, these apoptotic genes were largely suppressed in ACs (**Figure [3](#F3){ref-type="fig"}B**). In the flow cytometry assay, we also found FasL was greatly increased in TCs but not in ACs (**Figure [3](#F3){ref-type="fig"}C**), while Fas was not markedly affected (**Figure [3](#F3){ref-type="fig"}D**). We then assessed whether aspirin activates downstream molecules of the FasL pathway. As shown in **Figure [S3](#SM0){ref-type="supplementary-material"}A**, cleaved caspase-3 and caspase-8 proteins were markedly increased in TCs. Thus, downstream molecules of the FasL pathway were highly activated in colorectal CSCs following aspirin treatment. Next, we determined whether FasL is required for aspirin-induced apoptosis. TCs of HT29 cells were treated with 5 mM aspirin in the presence or absence of neutralizing antibody Nok-1. As indicated by cell viability assays (**Figure [3](#F3){ref-type="fig"}E**), flow cytometry (**Figure [3](#F3){ref-type="fig"}F**), and TUNEL assays (**Figure [S3](#SM0){ref-type="supplementary-material"}B**), aspirin-induced apoptosis in TCs was significantly attenuated by Nok-1, suggesting that aspirin-induced apoptosis in CSCs requires the activation of FasL.

We next questioned whether aspirin stimulates the expression of FasL and induces apoptosis in a COX-2-dependent pathway (**Figure [S3](#SM0){ref-type="supplementary-material"}C**). *COX-2* mRNA and enzyme activity were tested in both ACs and TCs, and no significant differences were found (**Figure [S3](#SM0){ref-type="supplementary-material"}D-F**). As shown in **Figure [S3](#SM0){ref-type="supplementary-material"}C**, siRNAs against *COX-2*, a selective inhibitor of COX-2, NS-398, or a substrate of the COX-2 pathway, PGE2, were used to assess both the sufficiency and necessity of COX-2 signaling in aspirin-induced apoptosis. The efficiencies of NS-398 and PGE2 were assessed in **Figure [S3](#SM0){ref-type="supplementary-material"}G**. Inhibition of COX-2 with either siRNAs or NS-398 failed to induce apoptosis or FasL expression (**Figure [3](#F3){ref-type="fig"}G, H** and **Figure [S3](#SM0){ref-type="supplementary-material"}H-I**). In addition, aspirin-induced apoptosis or FasL upregulation was not attenuated by the addition of PGE2 (**Figure [3](#F3){ref-type="fig"}I-J** and **Figure [S3](#SM0){ref-type="supplementary-material"}H-I**). These results suggest that aspirin induces apoptosis and FasL expression in colorectal CSCs independent of COX-2 inhibition.

Aspirin promotes the acetylation of histone H3
----------------------------------------------

We compared the effects of aspirin on stimulating FasL expression in CSCs (**Figure [4](#F4){ref-type="fig"}A**) with other NSAIDs including salicylic acid, ibuprofen, sulindac, and indomethacin after 48 h treatment (**Figure [S4](#SM0){ref-type="supplementary-material"}A**). Interestingly, aspirin, but not any of the other NSAIDs, stimulated FasL expression. Compared to other NSAIDs, aspirin has a unique structural feature and possesses an acetyl moiety (**Figure [4](#F4){ref-type="fig"}B** and **Figure [S4](#SM0){ref-type="supplementary-material"}B**), which led us to investigate whether the acetylation of aspirin plays a role in aspirin-induced effects. Given that *FasL* is exclusively induced by aspirin, that acetylation of histone H3 in the*FasL* promoter region enhances its transcription in endothelial cells, and that aspirin acetylates histone proteins [@B16], we assessed whether aspirin induces *FasL* expression by acetylating histones in CSCs. We found histone deacetylase inhibitor trichostatin A (TSA, 1 μM) significantly increased FasL expression in HT29 TCs (**Figure [4](#F4){ref-type="fig"}C-D**) but not in ACs (**Figure [4](#F4){ref-type="fig"}E-F**), suggesting that histone acetylation in CSCs drives FasL expression. Furthermore, we observed that H3K9 was significantly acetylated following aspirin treatment (**Figure [4](#F4){ref-type="fig"}G**). Next, chromatin immunoprecipitation (ChIP) assay showed that aspirin treatment enriched the acetylated histone H3K9 (ac-H3K9) on the promoter of *FasL*, and this effect was only observed in HT29 TCs but not ACs (**Figure [4](#F4){ref-type="fig"}H**).

Of interest, it has been proposed that histone H3 is hypermethylated in ACs [@B40], raising the possibility that the hypermethylation of H3K9 in ACs prevents aspirin-induced FasL expression. Indeed, when monomethylation of H3K9 was evaluated (**Figure [4](#F4){ref-type="fig"}I**), the level of methylated H3K9 in ACs was found to be notably higher than that in TCs. In ACs, aspirin promoted the acetylation of H3K9 only when a methyltransferase inhibitor 5-aza-dC was added (**Figure [4](#F4){ref-type="fig"}I**). In accordance with the observed acetylation, FasL expression was also induced in ACs with aspirin and 5-aza-dC co-treatment (**Figure [4](#F4){ref-type="fig"}J**). These results demonstrate that aspirin induces FasL expression in TCs by promoting histone H3K9 acetylation and that this effect is occluded in ACs due to hypermethylation of the same residue.

Acetylation of histone H3 activates FasL transcription and promotes apoptosis
-----------------------------------------------------------------------------

Aspirin is known to acetylate multiple substrates from nucleic acids to proteins [@B41]. To assess whether aspirin directly interacts with and acetylates histone H3, we chemically conjugated biotin to aspirin (**Figure [S5](#SM0){ref-type="supplementary-material"}A-E**) and synthesized biotinylated aspirin (**Figure [5](#F5){ref-type="fig"}A**, Biotin-Asp). The cell viability assays suggested that Biotin-Asp retained similar inhibitory effects as aspirin (**Figure [5](#F5){ref-type="fig"}B**). As shown in **Figure [5](#F5){ref-type="fig"}C**, co-localization of immunoreactive signals of biotin and DAPI demonstrated that aspirin is localized to nuclei. The co-IP these imaging data suggest an association of signals may be present between aspirin and histone H3 in the nucleus (**Figure [5](#F5){ref-type="fig"}D**).

Although we observed that aspirin induces the acetylation of histone H3 on the promoter of *FasL*, the physiological significance of this specific modification is still undetermined given that traditionally used approaches, such as TSA, cause genome-wide alterations via histone modification. To assess the causal effects of aspirin-induced acetylation of histone H3, we modified recently developed programmable reagents based on transcription activator-like effectors (TALEs) [@B42] to achieve control of epigenetic modification. Briefly, we fused four concatenated mSin3 interaction domains (SID4X) that are able to reduce H3K9 acetylation with a catalytically dead Cas9 (dCas9) (**Figure [5](#F5){ref-type="fig"}E**). To allow SID4X-dCas9 protein to specifically bind to and remove histone acetylation on the promoter of *FasL*, four guide RNA (gRNA) sequences targeting different regions of the *FasL* promoter were designed and cloned into a plasmid containing SID4X-dCas9, driven by a U6 promoter (**Figure [5](#F5){ref-type="fig"}E** and **Figure [S5](#SM0){ref-type="supplementary-material"}J**). As shown in **Figure [5](#F5){ref-type="fig"}F** and **Figure [S5](#SM0){ref-type="supplementary-material"}I**, both aspirin-induced *FasL* expression and apoptosis were significantly attenuated by all four vectors expressing gRNAs.

To acutely modulate the acetylation of H3K9 on the *FasL* promoter, we further developed a light-inducible histone modification system by introducing a light-stimulated CRY2/CIB1 protein pair (**Figure [5](#F5){ref-type="fig"}G**). In this system, SID4X fused with CRY2PHR, a truncated light-sensitive cryptochrome 2 protein consisting of the photolyase homology region, was employed as previously described [@B33]. CIB1, which interacts with CRY2PHR upon light stimulation, was instead fused with dCas9. gRNA \#1 and \#4, which exhibited higher efficiency in guiding SID4X-dCas9 (F**igure 5F**), were cloned into the same plasmid and driven by a U6 promoter (**Figure [5](#F5){ref-type="fig"}G**). As shown in **Figure [5](#F5){ref-type="fig"}H**, transfection of the plasmids, *i.e.*, CRY2PHR-SID4X, CIB1-dCas9, or gRNA-CIB1-dCas9, into HT29 TCs caused no significant changes in aspirin-induced expression of *FasL* when the cells were incubated in the dark (open bars). This system was stable under 24 h illumination, and 5 mW/cm^2^ 466 nm blue light (**Figure [S5](#SM0){ref-type="supplementary-material"}E-H**). When the cells were illuminated for 24 h with 466 nm blue light, which induces the dimerization of CRY2PHR and CIB1 and, therefore, the anchoring of SID4X to the *FasL* promoter with the gRNA/dCas9 complex, aspirin-induced *FasL* expression was significantly attenuated (**Figure [5](#F5){ref-type="fig"}H**). Notably, similar light illumination of un-transfected HT29 TCs had no marked effects on *FasL* expression; light illumination also did not change aspirin-induced *FasL* expression in the absence of gRNA (**Figure [5](#F5){ref-type="fig"}H**). Taken together, these results demonstrate that specific acetylation of histone H3K9 on the promoter of *FasL* is directly required for the aspirin-induced effects in CSCs.

p300 is required for aspirin-induced acetylation of histone H3
--------------------------------------------------------------

The histone acetyltransferases (HATs) that are known to enhance H3K9 acetylation include p300, CREB-binding protein (CBP), p300/CBP-associated factor (PCAF), and GCN5L2. To determine which of the above HATs is required for aspirin-induced FasL, we designed siRNAs targeting *p300*,*CBP*,*PCAF*, and *GCN5L2* and verified their efficiencies (**Figure [S6](#SM0){ref-type="supplementary-material"}A-D**) in HT29 TCs. As shown in **Figure [6](#F6){ref-type="fig"}A-E**, only the siRNA against *p300* or a selective inhibitor against p300, C646, occluded aspirin-induced FasL expression. Similar results were also observed via flow cytometry (**Figure [S6](#SM0){ref-type="supplementary-material"}F-G**). These findings demonstrate that p300 but not PCAF, CBP or GCN5 is required for aspirin-induced*FasL* expression in CSCs.

To determine whether p300 directly binds to the promoter region of *FasL*, a ChIP assay with antibodies against p300 was performed. As shown in **Figure [6](#F6){ref-type="fig"}E**, aspirin significantly increased the binding of p300 at the *FasL* promoter in HT29 TCs, and the binding was disrupted by either a siRNA against *p300* or its inhibitor. A direct interaction between aspirin and p300 was revealed based on their co-IP (**Figure [6](#F6){ref-type="fig"}F**). Overall, these imaging data suggest an association of signals may be present between aspirin and p300, and p300 is recruited by aspirin in CSCs and is required for aspirin-induced acetylation of histone H3.

Aspirin suppresses oxaliplatin-enriched CSCs
--------------------------------------------

To explore the potential of aspirin serving as an adjuvant therapy in CRC treatment, we treated the TCs and ACs with oxaliplatin, a first-line chemotherapeutic drug for colon cancer. In line with our prior findings, we found that TCs showed resistance to oxaliplatin compared to ACs, while 5 mM aspirin significantly sensitized oxaliplatin-induced cell death in TCs (**Figure [7](#F7){ref-type="fig"}A-B**), as evidenced by the reduced 50% inhibitory concentration (IC50) of oxaliplatin (**Table [S3](#SM0){ref-type="supplementary-material"}**). Given the different effects of aspirin on ACs and TCs, we expected that aspirin combined with oxaliplatin would exert a synergistic effect on inhibiting CRC. As shown in **Figure [7](#F7){ref-type="fig"}C**, both aspirin and oxaliplatin treatments decreased the number of viable cells, and the combination of aspirin and oxaliplatin induced a much greater reduction. The majority of tumor cells lose their CSC properties during tumor growth in vivo. It has been reported that oxaliplatin treatment can enrich the TC /CSC [@B6], [@B31]. We then employed oxaliplatin to enrich the CSCs and tested the effect of aspirin on them. We observed that the tumor volumes significantly decreased in the group of mice administered both aspirin and oxaliplatin compared with the group of mice treated with oxaliplatin only (**Figure [7](#F7){ref-type="fig"}D**). These results demonstrate that aspirin can inhibit oxaliplatin-enriched colorectal CSCs.

Then, we tested whether aspirin exerts these effects by activating Ac-H3K9-FasL signaling pathway in the tumor tissue. We observed that CSCs (ALDH-positive cells) were significantly enriched in the oxaliplatin treatment group, while the number of CSCs (ALDH-positive cells) decreased dramatically in the aspirin combined oxaliplatin treatment group (**Figure [7](#F7){ref-type="fig"}F**). In addition, aspirin combined oxaliplatin treatment induced significant apoptosis compared with the group of mice treated with oxaliplatin only (**Figure [7](#F7){ref-type="fig"}E**). The expression of FasL and Ac-H3K9 increased obviously in the group with aspirin combined oxaliplatin treatment (**Figure [7](#F7){ref-type="fig"}F-G**). Taken together, these results showed that aspirin suppresses oxaliplatin-enriched CSCs by activating Ac-H3K9-FasL signaling pathway; thus, it may serve as an adjuvant therapy in CRC treatment.

Discussion
==========

CSCs are a small population of cells found within tumors that exhibit self-renewal, differentiation, and resistance to conventional therapies [@B7]. Their existence has been strongly implicated in carcinogenesis and tumor progression in CRC patients [@B43]. Many recent studies have focused on CSCs and have sought to develop strategies to selectively eliminate them, but efficient and specific drugs are still lacking. In the current study, we found that aspirin, a widely used NSAID, can serve as an efficient anti-CSC agent. We further demonstrated that aspirin inhibits CSCs by inducing FasL-mediated apoptosis. Importantly, we revealed a unique epigenetic pathway that underlies these effects, *i.e.*, aspirin interacts directly with p300 and histone H3 in the nucleus, promotes the acetylation of H3K9 on the promoter of the *FasL* gene, and transcriptionally activates FasL expression. Notably, we found that the aforementioned effects of aspirin are absent in non-CSCs due to the hypermethylation of H3K9, which occludes their acetylation (**Figure [6](#F6){ref-type="fig"}G**). More importantly, aspirin suppresses oxaliplatin-enriched CSCs and sensitized CSCs to oxaliplatin. Our above findings have thus filled a major knowledge gap and identified aspirin as a unique agent that can target CSCs in CRC and serve as an adjuvant therapy besides traditional chemotherapy in CRC.

A few studies had suggested that aspirin decreases the number of CSCs in some types of cell lines [@B15], but *in vivo* evidence from patients is still lacking. In this study, we included CRC patients who were treated with or without aspirin at the second affiliated hospital of Zhejiang University School of Medicine from 2012 to 2016. Owing to the preventive effect of aspirin on CRC, we finally included 18 patients with CRC who were taking 75-100 mg aspirin daily. Thus, it is difficult to divide these patients into different subtypes according to sex, age and exposure time, or analyze the interindividual variability. We detected the ratio of CSCs in the CRC tissue from patients with or without aspirin treatment and found that patients taking aspirin had a lower percentage of CSCs and a better prognosis. However, more patients still need to be included in future studies to provide reliable evidence for the therapeutic effect of aspirin. Recently, an ongoing clinical trial (ADD-aspirin trial) has been initiated in patients with newly diagnosed cancers, including colorectal, gastroesophageal, breast, and prostate cancer, and is testing the efficacy of aspirin administration as an adjuvant for chemotherapy, which may offer us more evidence [@B44].

To test the effect of aspirin on CSCs *in vitro*, we treated TCs with different concentrations of aspirin (0-10 mM). It has been reported that low-dose aspirin (humans: 80-100 mg/day; mice: 20 mg/kg/day) can exert an antineoplastic effect. The concentration of aspirin used in this study is much higher than that in the human case. We chose the aspirin concentration range of 5-10 mM based on the following reasons. Firstly, aspirin was used daily for a long time in these clinical trials [@B10], [@B14], [@B45]. It was also reported that the ability of aspirin to reduce colorectal cancer incidence became evident only after regular use for more than 10 years, indicating that the effect was dependent upon both the dose and duration of aspirin intake. This suggested the importance of cumulative dosage as a determinant of aspirin efficacy in these settings [@B46]. Conversely, in the cell model, cancer cells were treated with aspirin once. Thus we adopted the concentration of aspirin which was widely used in previous studies [@B25], [@B47], [@B48]. Secondly, we treated the colorectal cancer stem-like cells with 1 mM daily for 5 days or 500 μM daily for 10 days, and found that lower concentration of aspirin exerted similar effects on colorectal cancer stem-like cells. Therefore, we used the most common concentration (5-10 mM) to test its effect in vitro. In the current study, we observed that aspirin can inhibit colorectal cancer stem-like cells and induce apoptosis. In addition, aspirin causes more reduction of TCs compared to ACs at the same time point. But, we did not offer more direct evidence that it selectively inhibits cancer stem cells in colorectal cancer, which needs more evidence in future studies. Inducing apoptosis is believed to be a superior strategy for eliminating CSCs. We found that the apoptosis induced by aspirin in CSCs requires the upregulation of FasL. These results demonstrate that FasL signaling is a promising route for eliminating CSCs and that the increased FasL expression following aspirin treatment could serve as a sensitive indicator of its efficacy. In addition, we found that Fas protein is significantly upregulated in CSCs. Fas is a prototypical death receptor that induces apoptosis upon ligand binding, and it is also a tumorigenic gene [@B49]. It has recently been observed that stimulation of Fas increases the number of CSCs in mouse colon cancer cell lines [@B50]. These findings suggest that Fas could contribute to the maintenance of CSCs and mediate their resistance to conventional therapy. Additionally, increased expression of Fas in CRC samples could also be a viable clinical marker for aspirin-sensitive therapies in CRC patients.

Whether aspirin suppresses tumor growth and progression by inhibiting COX-2 signaling has been extensively discussed. However, we revealed that aspirin inhibits colorectal CSCs in a COX-2-independent manner. Specifically, we found that 1) inhibition of COX-2 with either siRNAs or its selective inhibitor fails to reproduce the aspirin-induced effects; 2) the addition of PGE2, the functional product of COX-2 activation, fails to attenuate aspirin-induced effects; and 3) other NSAIDs that inhibit COX-2 activity fail to mimic aspirin\'s effects. These results strongly suggest that aspirin is engaged in a mechanism other than COX-2 inhibition to inhibit CSCs.

Compared to the chemical structures of other NSAIDs, aspirin exhibits a unique feature as it possesses an acetyl moiety, which makes it an efficient acetylating compound. Indeed, in past decades, a variety of bioactive molecules have been identified as substrates of aspirin-mediated acetylation. In addition to COX enzymes, aspirin can also acetylate DNA, RNA, metabolites, and proteins including p53, hemoglobin, transglutaminase, and histones [@B16], [@B26]-[@B30]. The biological consequences of aspirin-mediated acetylation, however, are largely undetermined. Especially, the acetylation of histone plays a vital role in epigenetic regulation of genes. In the current study, we found that aspirin could interact with acetyltransferase p300, and acetylate histone H3 at its H3K9 lysine residue. We further demonstrated that such acetylating modification of histone proteins is required for aspirin-induced, FasL-mediated apoptosis of CSCs, while it is prevented in non-CSCs due to hypermethylation of histone H3K9 residues. Importantly, to understand whether aspirin directly acetylates histones in the promoter region of *FasL*, we improved and established locus-specific histone modification (LSHM) and light-inducible LSHM systems based on CRIPSR/dCas9 technology. The results from these state-of-art approaches provide the critical evidence that histone acetylation mediates the anti-cancer effects of aspirin. Given the significance of histone acetylation in a variety of biological and cellular processes, the epigenetic modification of aspirin on histones could have broader meanings and provide a more universal basis for understanding the multifaceted effects of aspirin.

Finally, although aspirin has been reported to reduce the overall mortality of CRC and the risk of distant tumor metastasis [@B11], [@B12], treatments including aspirin as an adjuvant drug for CRC are still a topic of debate. The current study represents a critical advance toward clinical applications of aspirin in cancer therapy, and the molecular pathway revealed here could provide important guidelines regarding its clinical prescription. Our findings that aspirin exerts synergistic anti-neoplastic effects with oxaliplatin suggest that aspirin could be administered with traditional chemotherapy drugs in CRC treatments. Additional evidence from clinical studies is thus anticipated in the near future.
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CSCs

:   cancer stem-like cells
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:   colorectal cancer
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:   clustered regularly interspaced short palindromic repeats
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:   cyclooxygenase-2
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:   adherent cells

TCs
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:   one-way analysis of variance
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:   CREB-binding protein
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:   p300/CBP-associated factor
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:   chromatin immunoprecipitation

IC50

:   50% inhibitory concentration

LSHM

:   locus-specific histone modification.

![**Aspirin treatment eliminates colorectal CSCs. (A-B)** Representative images (left) and quantification (right) of immunostaining assays used to detect the percentage of colorectal CSCs (ALDH1+, DLCK1+) in tumor cells in the paraffin specimens of patients. Scale bar indicates 100 μm. CRC: colorectal cancer. The results are presented as the mean ± SEM, n=3. \*, p\<0.01, unpaired t-test. **(C-D)** Tumorsphere-forming assay. Representative images **(E)** and quantification **(F)** of TCs (tumor spheres) formed from three colorectal cancer cell lines (HT29, P1, or P2) following 14-day treatment with aspirin (Asp) at the indicated concentrations. Tumor spheres formed from the adherent cells (ACs) of each cell line were also included. The results are presented as the mean ± SEM, n=3. \*, p\<0.01, one-way ANOVA. **(E)** The activity of ALDH1 analyzed using the ALDEFLUOR assay; diethylaminobenzaldehyde (DEAB) is a negative control, which was used to inhibit the reaction of ALDH with the ALDEFLUOR reagent. ALDH1-positive cells and their average percentages in the total cell counts are indicated in each panel (mean ± SEM, n=3). **(F)** Quantitative PCR (qPCR) results from HT29 and P1 ACs, TCs, or TCs with 2-day Asp treatment (5 mM) (mean ±SEM, n=3, normalized to *Gapdh* mRNA expression). \*, p\<0.01, one-way ANOVA compared to TCs without Asp treatment. **(G)** Tumor growth curve from xenograft assays following subcutaneous injection of 1×10^5^ TCs of HT29 cells into 6-week-old female nude mice (mean ± SEM, n=6). *In vivo* effects of Asp analyzed by*i.p*. injection of 20 mg/kg Asp following the seeding of TCs. \*, p\<0.01, two-way ANOVA compared to untreated TCs at the indicated time points. (See also **Figure [S1](#SM0){ref-type="supplementary-material"}**, **Table [S1](#SM0){ref-type="supplementary-material"}** and **Table [S2](#SM0){ref-type="supplementary-material"}**)](thnov08p4447g001){#F1}

![**Aspirin selectively induces apoptosis in CSCs. (A)** Proliferation analysis of the survival of cells following 24 and 48 h exposure to Asp at the indicated concentrations. The results of Asp treatment of TCs from HT29 and P1 cell lines are presented (mean ±SEM, n=3). \*, p\<0.01, one-way ANOVA. **(B)** ALDH1 expression analyzed via FCM assays of ACs from HT29 and P1 cell lines, following 2-day treatment with Asp at the indicated concentrations. ALDH1 immunoreactive cells and their average percentages of the total cell counts are indicated in each panel (mean ± SEM, n=3). **(C-D)** TUNEL assay. Representative images (C) and quantification (D) of apoptotic cells of TCs from HT29 or P1 cell lines following 2-day treatment with Asp at the indicated concentrations. Scale bar in (C) indicates 50 μm. (D) The results are presented as the mean ± SEM, n=3. \*, p\<0.01, one-way ANOVA. **(E)** Cell cycle distributions analyzed via FCM assays of HT29 ACs or TCs following treatment with 5 mM Asp at the indicated time points. Sub-G1 was designated the apoptotic proportion and is listed in each panel (mean ± SEM, n=3). (See also **Figure [S2](#SM0){ref-type="supplementary-material"}**)](thnov08p4447g002){#F2}

![**Aspirin-induced apoptosis is mediated by FasL. (A-B)** qPCR results of HT29 and P1 TCs (A) or ACs (B) following 2-day treatment with 5 mM Asp (mean ±SEM, n=3, normalized to *Gapdh* mRNA expression). \*, p\<0.01, one-way ANOVA. The control is set to 1 for every gene. **(C-D)** FasL and Fas expression in HT29 TCs (C) or ACs (D) analyzed via FCM assays. Immunoreactive cells and their average percentages of the total cell counts are indicated in the histogram and quantified (mean ± SEM, n=3). \*, p\<0.01, unpaired t-test. **(E)** Proliferation analysis of the survival of HT29 and P1 TCs following 48 h exposure to 5 mM Asp in the presence of an isotype-matched control antibody or FasL-blocking antibody (Nok-1) at the indicated concentrations (mean ±SEM, n=3). \*, p\<0.01, one-way ANOVA. **(F)** Representative results of HT29 TCs analyzed via FCM assays following 48 h exposure to 5 mM Asp with a control antibody or 2 μg/mL Nok-1. Sub-G1 was designated as the apoptotic proportion. Scale bar indicates 50 μm. **(G-J)** TUNEL assay (G, I) and FCM assay (H, J) for analyzing apoptotic cells and FasL expression, respectively, from HT29 TCs in the presence of Asp (5 mM), Asp (5 mM) and PGE2 (1 μM) co-treatment, and siRNA against *COX-2* or NS-398 (75 μM). The results are presented as the mean ± SEM, n=3. \*, p\<0.01, one-way ANOVA. (See also **Figure [S3](#SM0){ref-type="supplementary-material"}**)](thnov08p4447g003){#F3}

![**Aspirin promotes the acetylation of histone H3. (A)** FCM assay of FasL expression in HT29 TCs in the presence of Asp (5 mM), salicylic acid (5 mM), ibuprofen (1 mM), sulindac (100 μM) or indomethacin (600 μM). The results are presented as the mean ± SEM, n=3. \*, p\<0.01, one-way ANOVA. **(B)** Chemical structure of aspirin. The red square indicates its acetyl moiety. **(C-F)** Expression of FasL in HT29 TCs (C-D) or ACs (E-F) in the presence of Asp (5 mM) or TSA (1 μM) analyzed via FCM assays. FasL immunoreactive cells and their average percentage of the total cell counts are indicated (C, E) and quantified (D, F) (mean ± SEM, n=3). \*, p\<0.01, one-way ANOVA. **(G)** Immunoblotting analysis with anti-acetylated antibodies against H2AK5, H2BK5, H3K9, or H4K8 of HT29 or P1 TCs after 48 h Asp treatment. **(H)** *In vitro* ChIP assay using antibodies against Ac-H3K9 followed by qPCR to detect a fragment on the promoter of the *FasL* gene of HT29 TCs or ACs treated with 5 mM Asp (mean ± SEM, n=3, normalized to the expression level of 10% input). \*, p\<0.01, unpaired t-tests. **(I)** Immunoblotting against Mono-Me-H3K9 of ACs or TCs from HT29 and P1 cell lines. Immunoblotting against Ac-H3K9. **(J)** FCM assay of FasL expression in HT29 ACs in the presence of Asp (5 mM), 5-AZA (5 μM), or both Asp (5 mM) and 5-AZA (5 μM). The average percentages of FasL immunoreactive cells in the total cell counts were quantified (mean ± SEM, n=3). \*, p\<0.01, one-way ANOVA. (See also **Figure [S4](#SM0){ref-type="supplementary-material"}**)](thnov08p4447g004){#F4}

![**Locus-specific analysis of aspirin-induced acetylation of histone H3K9. (A)** Chemical structures of Biotin-Asp and Biotin-NH~2~. **(B)** Proliferation analysis of the survival of HT29 or P1 TCs following 48 h exposure to 5 mM Asp, Biotin-NH~2~, or Biotin-Asp (mean ±SEM, n=3). \*, p\<0.01, one-way ANOVA. **(C)** Immunocytochemical fluorescence staining with antibodies against biotin in HT29 TCs treated with 5 mM Biotin-NH~2~ or Biotin-Asp for 48 h. Scale bar indicates 10 μm. **(D)** *In vitro* IP assay. After 48 h treatment with 5 mM Biotin-NH~2~ or Biotin-Asp, HT29 TCs lysates were immunoprecipitated with anti-Biotin antibodies and immunoblotted with antibodies against Ac-H3K9 or GAPDH. **(E)** Schematics of locus-specific histone modification based on the CRISPR/dCas9 system (upper) and the associated gRNA-SID4X-dCas9 vector design (lower). **(F)** qPCR results of *FasL* mRNA from HT29 TCs transfected with the indicated plasmids (mean ±SEM, n=3, normalized to *Gapdh* mRNA expression) following 5 mM Asp treatment. \*, p\<0.01, one-way ANOVA. **(G)** Schematics of light-inducible locus-specific histone modification (upper) and the associated vectors (lower). **(H)** qPCR results of *FasL* mRNA from HT29 TCs transfected with the indicated plasmids (mean ± SEM, n=3, normalized to *Gapdh* mRNA expression); 5 mM Asp and 5 mW/cm^2^ 466 nm blue light were applied as indicated. \*, p\<0.01, unpaired t-test. (See also **Figure [S5](#SM0){ref-type="supplementary-material"}**)](thnov08p4447g005){#F5}

![**p300 is required for aspirin-induced acetylation of histone H3. (A-D)** FCM assay of FasL expression in HT29 TCs treated with 5 mM Asp in the presence of siRNA against *p300* or its inhibitor C646 (10 μM) (A), or siRNAs against *CBP* (B), *PCAF* (C), or *GCN5L2* (D) (mean ± SEM, n=3). \*, p\<0.01, one-way ANOVA. **(E)** *In vitro* ChIP assay with antibodies against p300 followed by qPCR to detect fragments on the promoter of the *FasL* gene in HT29 TCs treated with 5 mM Asp, siRNA against *p300*, or C646 (mean ± SEM, n=3, normalized to the expression level of 10% input). \*, p\<0.01, one-way ANOVA. **(F)** *In vitro* IP assay. After 48 h treatment with 5 mM Biotin-NH~2~ or Biotin-Asp, HT29 TC lysates were immunoprecipitated with anti-Biotin antibodies and immunoblotted with antibodies against p300 or GAPDH. **(G)** Diagram summarizing the difference between aspirin-induced effects in CSCs (upper) and non-CSCs (lower). (See also **Figure [S6](#SM0){ref-type="supplementary-material"}**)](thnov08p4447g006){#F6}

![**Aspirin suppresses oxaliplatin-enriched CSCs**. **(A-B)** Proliferation analysis of the survival of cells following 48 h exposure to Oxa at the indicated concentrations. The results of ACs, TCs, or TCs with Asp and Oxa co-treatment (5 mM) from the HT29 (A) or P1 (B) cell lines are presented (mean ±SEM, n=3). **(C)** Proliferation analysis of the survived cells following 48 h treatment with saline (Control group), Oxa (20 μg/mL), Asp (5 mM), or both Oxa and Asp. ACs from both HT29 and P1 cell lines were used. The data are presented as the mean ±SEM. \* p\<0.01, one-way ANOVA. **(D)** Tumor growth curve from xenograft assays following subcutaneous injection of 1×10^5^ HT29 TCs into 6-week-old female nude mice. The data are presented as the mean ± SEM and n=6 for each group. *In vivo* effects of Asp were analyzed by *i.p.* injection of both Asp (daily, 20 mg/kg body weight) and Oxa (once a week, 2 mg/kg/body weight) 10 days after seeding of TCs. The data are presented as the mean ± SEM. \*, p\<0.01 two-way ANOVA. **(E)** Representative images of TUNEL assays for detecting apoptotic cells from tumor tissues derived from HT29 TCs after Oxa treatment or both Oxa and Asp co-treatment. Scale bar indicates 20 μm. **(F)** Representative results of H&E staining and immunohistochemistry against ALDH1, FasL and ac-H3K9 on xenograft tumor sections from HT29 TCs mice treated with Oxa (once a week, 2 mg/kg/body weight) or Oxa combined with Asp (20 mg/kg body weight). Scale bar indicates 50 μm. **(G)** Quantification of immunohistochemistry on FasL or Ac-H3K9 positive cells in the tumors. Five visual fields were randomly selected and 100 cells in each visual field were counted. Data are shown as the percentage of the total number of positive cells. Values are presented as means ± SD, n=4. \*P\<0.05.](thnov08p4447g007){#F7}
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